Navigation Links
Statement from Ralph G. Neas, President and CEO, Generic Pharmaceutical Association, on the Front Page New York Times Story Regarding the Pre-emptive Strikes of Amgen/Genentech to Restrict Access to Affordable and Safe Biosimilars
Date:1/29/2013

WASHINGTON, Jan. 29, 2013 /PRNewswire-USNewswire/ --Today's story shines a light on what essentially is a pre-emptive strike by Amgen and Genentech designed to choke the flow of safe and affordable life-saving biologic medicines to patients even before these products have been approved by the Food and Drug and Administration (FDA).  This is unfortunate because it puts profits ahead of the patients who need these treatments but many times cannot get them because of their prohibitively high cost.

The efforts highlighted in the Times story are doubly worrying for state legislators because not only will they slow availability of safe, effective and more affordable therapies to patients, but they also will dramatically decrease the much-needed cost savings that biosimilars will provide. At a time when legislators are desperately seeking ways to keep their state fiscally sound, these bills will encourage needless and wasteful spending on name brand therapies even after FDA-approved lower cost biosimilar products become available.

While in the guise of supporting biosimilar efforts, Amgen and Genentech are making every effort to limit consumer and patient access to safe and effective biosimilars in the future.

Biosimilar medicines, which are less costly versions of brand-name biologics, have been used safely in Europe for nearly seven years.  However, these affordable treatments are not yet available in the U.S.  But under new federal laws, the FDA now is developing regulations that will allow for the approval and use of biosimilars here at home.  Make no mistake: patient safety is paramount both for the FDA and for the companies that will make these medicines.  In fact, many of the companies who are working to develop biosimilars are the same companies now making brand name biologics.

As the Times story correctly notes, efforts by brand companies to erect barriers to competition from lower cost generic versions of their drugs have been going on for decades.  But as is true with traditional prescription drugs, competition from safe, effective and more affordable biosimilars will, in the coming years, provide patients the savings they need while delivering the lifesaving therapy they depend upon.

According to an analysis by IMS Health published August 2, 2012, generic medicines saved the U.S. health care system more than $1 trillion over the past decade, $192 billion in 2011 alone.  We are confident that the use of safe and effective bisimilars will achieve similar savings.

GPhA represents the manufacturers and distributors of finished generic pharmaceuticals, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals fill 80 percent of the prescriptions dispensed in the U.S. but consume just 27 percent of the total drug spending. Additional information is available at gphaonline.org.

Generic Pharmaceutical Association - 777 Sixth Street, NW, Suite 510 - Washington, D.C. 20001


'/>"/>
SOURCE Generic Pharmaceutical Association
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Icahn Issues Statement Regarding Amylin Pharmaceuticals
2. American Society of Hematology Statement on Senate Passage of Prescription Drug User Fee Act (PDUFA)
3. American Society of Hematology Statement on House Passage of Prescription Drug User Fee Act (PDUFA)
4. Millennium Laboratories Wins Lawsuit: Ameritox Advertisements Regarding Rx Guardian and Rx Guardian CD Contain Literally False Statements
5. Statement from the Cystic Fibrosis Foundation on Passage of the EXPERRT Act in House of Representatives
6. Lilly Statement on PDUFA Vote by Senate
7. Statement from the Cystic Fibrosis Foundation on Passage of the EXPERRT Act in the U.S. Senate
8. Lilly Statement on Affordable Care Act Ruling by Supreme Court
9. Statement from Mary Vogt, President of Home Access Health Corporation, manufacturer of the Home Access HIV-1 test system, the only over-the-counter HIV test previously approved by the FDA for at-home use.
10. CRE Statement on "Inherent Reasonableness" for Retail Pharmacy Diabetic Supplies
11. Johnson Health Tech Statement on Lance Armstrong
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/9/2017)... 9, 2017 Zimmer Biomet Holdings, Inc. (NYSE ... today announced it has earned a spot on ... The Company was ranked among 500 U.S. employers as ... Healthcare Equipment and Services. The annual ... anonymous, independent survey of over 30,000 employees across 25 ...
(Date:5/9/2017)... 9, 2017  Semler Scientific, Inc. (OTCQB: SMLR), ... to improve the clinical effectiveness and efficiency of ... first quarter ended March 31, 2017. ... customers to identify when preventive care options are ... like heart attacks or strokes occur," said ...
(Date:5/6/2017)... 5, 2017   Provista , a proven leader in ... customers, today announced Jim Cunniff as the company,s ... and business experience to Provista, including most recently serving as ... California . He assumed his new role with ... great fit for Provista," says Jody Hatcher , president, ...
Breaking Medicine Technology:
(Date:5/24/2017)... ... 24, 2017 , ... NucleusHealth ™, advancing clinical practice ... Food and Drug Administration (FDA) 510(k) clearance for its Nucleus.io ... for medical image management. At the core is patented streaming technology that provides ...
(Date:5/24/2017)... DC (PRWEB) , ... May 24, 2017 , ... ... Center for Global Policy Solutions is vehemently opposed to Donald Trump’s budget, “A ... formula for despair that inspires fear, demonizes the poor, marginalizes underserved populations, undermines ...
(Date:5/24/2017)... ... 2017 , ... Medic CE , a Career Step company, is sponsoring ... hosted by the Journal of Emergency Medical Services (JEMS). The free webinar, to be ... by Captain Rommie Duckworth, LP, a career fire captain as well as founder and ...
(Date:5/24/2017)... ... May 24, 2017 , ... Rob Lowe is a sought after ... Public Television. “Informed” brings the public important topics from all aspects of life, and ... feet and issues surrounding feet and ankles. , Podiatry is essential to people’s overall ...
(Date:5/24/2017)... ... May 24, 2017 , ... Dymedix® ... diagnostics sensors, announced today it had completed the first phase of building a ... domestic and rest of world (ROW) authorized dealers specializing in polysomnography accessories. ...
Breaking Medicine News(10 mins):